What is the current stock price of Contineum Therapeutics, Inc. Class A Common Stock (CTNM)?

As of the latest market data, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is trading at $13.44. The stock has seen a loss of -1.90% today.

Does Contineum Therapeutics, Inc. Class A Common Stock (CTNM) pay a dividend?

Based on current data, Contineum Therapeutics, Inc. Class A Common Stock does not have a confirmed active dividend policy.

What is the market cap of Contineum Therapeutics, Inc. Class A Common Stock?

The current market capitalization of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is approximately unavailable.

CTNM

Contineum Therapeutics, Inc. Class A Common Stock·Healthcare

13.44

1.898%(−0.26)

Close Price

14.39

7.068%(+0.95)

After Hours

Last Updated: — ET

52W L: $3.3552W H: $16.33

CTNM NEWS

zacks.com

2d ago

Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?

The consensus price target hints at a 60% upside potential for Contineum Therapeutics, Inc. (CTNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

marketbeat.com

5d ago

Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential

Contineum Therapeutics NASDAQ: CTNM President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent exploratory pain data may point to additional clinical opportunities for the LPA1 receptor antagonist.

businesswire.com

May 15

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on May 14, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 51,000 shares of Class A common stoc.

businesswire.com

May 12

Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th at 3:35 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section.

businesswire.com

May 11

Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced two scientific posters for its lead investigational drug candidate, PIPE-791, at the upcoming American Thoracic Society (ATS) 2026 International Conference. ATS 2026 will take place in Orlando, Fla. from May 15-20, 20.

zacks.com

May 8

Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 49.2% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Company Profile

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2024-04-05

Beta

0.89

Websitewww.contineum-tx.com↗